DB:2K4

Stock Analysis Report

Executive Summary

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications.

Rewards

Revenue is forecast to grow 78.23% per year

Revenue grew by 351.1% over the past year

Risk Analysis

Earnings are forecast to decline by an average of -23.1% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 1 more risk


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has PhaseBio Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2K4's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.9%

2K4

1.0%

DE Biotechs

2.0%

DE Market


1 Year Return

65.5%

2K4

6.8%

DE Biotechs

15.1%

DE Market

Return vs Industry: 2K4 exceeded the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: 2K4 exceeded the German Market which returned 15% over the past year.


Shareholder returns

2K4IndustryMarket
7 Day-12.9%1.0%2.0%
30 Day-17.7%-1.2%1.0%
90 Day49.0%7.4%3.8%
1 Year65.5%65.5%7.1%6.8%18.6%15.1%
3 Yearn/a48.3%46.6%16.8%6.6%
5 Yearn/a11.4%9.0%23.7%6.7%

Price Volatility Vs. Market

How volatile is PhaseBio Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PhaseBio Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

1.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2K4's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2K4's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2K4 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2K4 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2K4's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2K4 is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is PhaseBio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-23.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2K4 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2K4 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2K4 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2K4's revenue (78.2% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 2K4's revenue (78.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2K4's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has PhaseBio Pharmaceuticals performed over the past 5 years?

-52.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 2K4 is currently unprofitable.

Growing Profit Margin: 2K4 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2K4's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 2K4's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2K4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 2K4 has a negative Return on Equity (-46.3%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is PhaseBio Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 2K4's short term assets ($83.4M) exceed its short term liabilities ($6.0M).

Long Term Liabilities: 2K4's short term assets ($83.4M) exceed its long term liabilities ($9.4M).


Debt to Equity History and Analysis

Debt Level: 2K4's debt to equity ratio (13.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 2K4's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 2K4 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 2K4's debt is covered by short term assets (assets are 8.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2K4 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 2K4 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -55.4% each year.


Next Steps

Dividend

What is PhaseBio Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 2K4's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2K4's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2K4's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2K4's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2K4's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Jonathan Mow (54yo)

4.9yrs

Tenure

US$595,630

Compensation

Mr. Jonathan P. Mow, MBA has been Chief Executive Officer of PhaseBio Pharmaceuticals, Inc. since March 2015 and serves as its President. Mr. Mow served as Chief Business Officer of PhaseBio Pharmaceutical ...


CEO Compensation Analysis

Compensation vs Market: Jonathan's total compensation ($USD595.63K) is above average for companies of similar size in the German market ($USD412.37K).

Compensation vs Earnings: Jonathan's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Mow
President4.9yrsUS$595.63k0.38% $480.0k
John Sharp
Chief Financial Officer3.8yrsUS$465.43k0.12% $153.8k
John Lee
Chief Medical Officer3.8yrsUS$501.05kno data
Kristopher Hanson
VP & Head of Legal0.3yrsno datano data
Michael York
Vice President of Corporate Development & Commercial Strategy1.7yrsno data0.0052% $6.6k
Glen Burkhardt
Vice President of Human Resources0.3yrsno datano data

2.8yrs

Average Tenure

54yo

Average Age

Experienced Management: 2K4's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jonathan Mow
President4.9yrsUS$595.63k0.38% $480.0k
Richard van den Broek
Independent Director1yrsno datano data
Edmund Harrigan
Independent Director1.2yrsUS$171.97kno data
Clay Thorp
Chairman of the Board0yrsUS$17.23k0.055% $69.4k
Caroline Loewy
Independent Director1.6yrsUS$124.59kno data
Nancy Hutson
Independent Director1.9yrsUS$80.60k0.0035% $4.4k
Peter Klein
Independent Director10.1yrsUS$9.12k0.0080% $10.1k
Alexander Sapir
Director0yrsno datano data

1.8yrs

Average Tenure

52.5yo

Average Age

Experienced Board: 2K4's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 3248.2%.


Top Shareholders

Company Information

PhaseBio Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PhaseBio Pharmaceuticals, Inc.
  • Ticker: 2K4
  • Exchange: DB
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$136.928m
  • Listing Market Cap: US$126.384m
  • Shares outstanding: 28.77m
  • Website: https://www.phasebio.com

Number of Employees


Location

  • PhaseBio Pharmaceuticals, Inc.
  • 1 Great Valley Parkway
  • Suite 30
  • Malvern
  • Pennsylvania
  • 19355
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHASNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2018
2K4DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2018

Biography

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 22:59
End of Day Share Price2020/02/17 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.